The cardiovascular risk of GH-deficient adolescents

Annamaria Colao, Carolina Di Somma, Mariacarolina Salerno, Letizia Spinelli, Francesco Orio, Gaetano Lombardi

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

To investigate the onset of the cardiovascular impairment in patients with GH deficiency (GHD), we prospectively studied cardiovascular risk parameters, cardiac mass and performance (by echocardiography) in 10 adolescent patients (5 with isolated GHD and 5 with multiple GHD) who reached their final height before GH replacement withdrawal, 6 months after GH replacement withdrawal, and 6 months after GH treatment was restarted, and in 10 sex- and age-matched controls. At study entry, when compared with controls, GHD adolescents had lower IGF-I levels (although still in the normal age range) and high-density lipoprotein (HDL)-cholesterol levels, higher total/HDL-cholesterol ratio, lower triglyceride levels, higher fibrinogen levels, and lower heart rate, systolic blood pressure, and early-to-late mitral flow velocity ratio (E/A). Left ventricular (LV) mass index and ejection fraction were normal. Six months after GH withdrawal, IGF-I levels decreased remarkably in all cases (from 176.6 ± 8.3 to 77.5 ± 8.9 μg/liter; P <0.001), whereas low-density lipoprotein-cholesterol and triglyceride levels significantly increased. The total/HDL-cholesterol ratio (from 3.89 ± 0.1 to 4.74 ± 0.2; P <0.05) and fibrinogen levels (from 261 ± 7.1 to 287.5 ± 6.4 mg/dl; P <0.05) also significantly increased compared with study entry, without any change in the other parameters. In contrast, both LV mass index (from 94.2 ± 1.6 to 87.8 ± 1.7 g/m2; P = 0.05) and E/A (from 1.32 ± 0.05 to 1.12 ± 0.03; P <0.01) decreased, although remaining in the normal range. Six months after restarting GH replacement (at a median dose of 10 μg/kg·d), lipid and cardiac parameters were brought back to the levels measured at study entry, but in no patient did IGF-I levels reach the 50th centile for age. HDL-cholesterol levels (P <0.0001), heart rate (P <0.05), systolic blood pressure (P <0.01), LV ejection fraction (P <0.005), and E/A (P <0.0001) remained lower, whereas total/HDL-cholesterol ratio (P <0.01), triglycerides, and fibrinogen levels (P <0.05) remained higher than controls. In conclusion, GH discontinuation is inappropriate in adolescents with severe GHD, inducing impairment of lipid profile and cardiac morphology and performance. Because the results on the cardiovascular system and on the lipid profile were suboptimal, it is likely that the GH dose in severe GHD adolescents should be higher.

Original languageEnglish
Pages (from-to)3650-3655
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume87
Issue number8
DOIs
Publication statusPublished - 2002

Fingerprint

HDL Cholesterol
Insulin-Like Growth Factor I
Fibrinogen
Blood Pressure
Blood pressure
Lipids
Reference Values
Triglycerides
Heart Rate
Pituitary Dwarfism
Echocardiography
Cardiovascular system
Cardiovascular System
Flow velocity
Stroke Volume
LDL Cholesterol
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

The cardiovascular risk of GH-deficient adolescents. / Colao, Annamaria; Somma, Carolina Di; Salerno, Mariacarolina; Spinelli, Letizia; Orio, Francesco; Lombardi, Gaetano.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 87, No. 8, 2002, p. 3650-3655.

Research output: Contribution to journalArticle

Colao, A, Somma, CD, Salerno, M, Spinelli, L, Orio, F & Lombardi, G 2002, 'The cardiovascular risk of GH-deficient adolescents', Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 8, pp. 3650-3655. https://doi.org/10.1210/jc.87.8.3650
Colao, Annamaria ; Somma, Carolina Di ; Salerno, Mariacarolina ; Spinelli, Letizia ; Orio, Francesco ; Lombardi, Gaetano. / The cardiovascular risk of GH-deficient adolescents. In: Journal of Clinical Endocrinology and Metabolism. 2002 ; Vol. 87, No. 8. pp. 3650-3655.
@article{441c20aaea384174996f8ca8105747f3,
title = "The cardiovascular risk of GH-deficient adolescents",
abstract = "To investigate the onset of the cardiovascular impairment in patients with GH deficiency (GHD), we prospectively studied cardiovascular risk parameters, cardiac mass and performance (by echocardiography) in 10 adolescent patients (5 with isolated GHD and 5 with multiple GHD) who reached their final height before GH replacement withdrawal, 6 months after GH replacement withdrawal, and 6 months after GH treatment was restarted, and in 10 sex- and age-matched controls. At study entry, when compared with controls, GHD adolescents had lower IGF-I levels (although still in the normal age range) and high-density lipoprotein (HDL)-cholesterol levels, higher total/HDL-cholesterol ratio, lower triglyceride levels, higher fibrinogen levels, and lower heart rate, systolic blood pressure, and early-to-late mitral flow velocity ratio (E/A). Left ventricular (LV) mass index and ejection fraction were normal. Six months after GH withdrawal, IGF-I levels decreased remarkably in all cases (from 176.6 ± 8.3 to 77.5 ± 8.9 μg/liter; P <0.001), whereas low-density lipoprotein-cholesterol and triglyceride levels significantly increased. The total/HDL-cholesterol ratio (from 3.89 ± 0.1 to 4.74 ± 0.2; P <0.05) and fibrinogen levels (from 261 ± 7.1 to 287.5 ± 6.4 mg/dl; P <0.05) also significantly increased compared with study entry, without any change in the other parameters. In contrast, both LV mass index (from 94.2 ± 1.6 to 87.8 ± 1.7 g/m2; P = 0.05) and E/A (from 1.32 ± 0.05 to 1.12 ± 0.03; P <0.01) decreased, although remaining in the normal range. Six months after restarting GH replacement (at a median dose of 10 μg/kg·d), lipid and cardiac parameters were brought back to the levels measured at study entry, but in no patient did IGF-I levels reach the 50th centile for age. HDL-cholesterol levels (P <0.0001), heart rate (P <0.05), systolic blood pressure (P <0.01), LV ejection fraction (P <0.005), and E/A (P <0.0001) remained lower, whereas total/HDL-cholesterol ratio (P <0.01), triglycerides, and fibrinogen levels (P <0.05) remained higher than controls. In conclusion, GH discontinuation is inappropriate in adolescents with severe GHD, inducing impairment of lipid profile and cardiac morphology and performance. Because the results on the cardiovascular system and on the lipid profile were suboptimal, it is likely that the GH dose in severe GHD adolescents should be higher.",
author = "Annamaria Colao and Somma, {Carolina Di} and Mariacarolina Salerno and Letizia Spinelli and Francesco Orio and Gaetano Lombardi",
year = "2002",
doi = "10.1210/jc.87.8.3650",
language = "English",
volume = "87",
pages = "3650--3655",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "8",

}

TY - JOUR

T1 - The cardiovascular risk of GH-deficient adolescents

AU - Colao, Annamaria

AU - Somma, Carolina Di

AU - Salerno, Mariacarolina

AU - Spinelli, Letizia

AU - Orio, Francesco

AU - Lombardi, Gaetano

PY - 2002

Y1 - 2002

N2 - To investigate the onset of the cardiovascular impairment in patients with GH deficiency (GHD), we prospectively studied cardiovascular risk parameters, cardiac mass and performance (by echocardiography) in 10 adolescent patients (5 with isolated GHD and 5 with multiple GHD) who reached their final height before GH replacement withdrawal, 6 months after GH replacement withdrawal, and 6 months after GH treatment was restarted, and in 10 sex- and age-matched controls. At study entry, when compared with controls, GHD adolescents had lower IGF-I levels (although still in the normal age range) and high-density lipoprotein (HDL)-cholesterol levels, higher total/HDL-cholesterol ratio, lower triglyceride levels, higher fibrinogen levels, and lower heart rate, systolic blood pressure, and early-to-late mitral flow velocity ratio (E/A). Left ventricular (LV) mass index and ejection fraction were normal. Six months after GH withdrawal, IGF-I levels decreased remarkably in all cases (from 176.6 ± 8.3 to 77.5 ± 8.9 μg/liter; P <0.001), whereas low-density lipoprotein-cholesterol and triglyceride levels significantly increased. The total/HDL-cholesterol ratio (from 3.89 ± 0.1 to 4.74 ± 0.2; P <0.05) and fibrinogen levels (from 261 ± 7.1 to 287.5 ± 6.4 mg/dl; P <0.05) also significantly increased compared with study entry, without any change in the other parameters. In contrast, both LV mass index (from 94.2 ± 1.6 to 87.8 ± 1.7 g/m2; P = 0.05) and E/A (from 1.32 ± 0.05 to 1.12 ± 0.03; P <0.01) decreased, although remaining in the normal range. Six months after restarting GH replacement (at a median dose of 10 μg/kg·d), lipid and cardiac parameters were brought back to the levels measured at study entry, but in no patient did IGF-I levels reach the 50th centile for age. HDL-cholesterol levels (P <0.0001), heart rate (P <0.05), systolic blood pressure (P <0.01), LV ejection fraction (P <0.005), and E/A (P <0.0001) remained lower, whereas total/HDL-cholesterol ratio (P <0.01), triglycerides, and fibrinogen levels (P <0.05) remained higher than controls. In conclusion, GH discontinuation is inappropriate in adolescents with severe GHD, inducing impairment of lipid profile and cardiac morphology and performance. Because the results on the cardiovascular system and on the lipid profile were suboptimal, it is likely that the GH dose in severe GHD adolescents should be higher.

AB - To investigate the onset of the cardiovascular impairment in patients with GH deficiency (GHD), we prospectively studied cardiovascular risk parameters, cardiac mass and performance (by echocardiography) in 10 adolescent patients (5 with isolated GHD and 5 with multiple GHD) who reached their final height before GH replacement withdrawal, 6 months after GH replacement withdrawal, and 6 months after GH treatment was restarted, and in 10 sex- and age-matched controls. At study entry, when compared with controls, GHD adolescents had lower IGF-I levels (although still in the normal age range) and high-density lipoprotein (HDL)-cholesterol levels, higher total/HDL-cholesterol ratio, lower triglyceride levels, higher fibrinogen levels, and lower heart rate, systolic blood pressure, and early-to-late mitral flow velocity ratio (E/A). Left ventricular (LV) mass index and ejection fraction were normal. Six months after GH withdrawal, IGF-I levels decreased remarkably in all cases (from 176.6 ± 8.3 to 77.5 ± 8.9 μg/liter; P <0.001), whereas low-density lipoprotein-cholesterol and triglyceride levels significantly increased. The total/HDL-cholesterol ratio (from 3.89 ± 0.1 to 4.74 ± 0.2; P <0.05) and fibrinogen levels (from 261 ± 7.1 to 287.5 ± 6.4 mg/dl; P <0.05) also significantly increased compared with study entry, without any change in the other parameters. In contrast, both LV mass index (from 94.2 ± 1.6 to 87.8 ± 1.7 g/m2; P = 0.05) and E/A (from 1.32 ± 0.05 to 1.12 ± 0.03; P <0.01) decreased, although remaining in the normal range. Six months after restarting GH replacement (at a median dose of 10 μg/kg·d), lipid and cardiac parameters were brought back to the levels measured at study entry, but in no patient did IGF-I levels reach the 50th centile for age. HDL-cholesterol levels (P <0.0001), heart rate (P <0.05), systolic blood pressure (P <0.01), LV ejection fraction (P <0.005), and E/A (P <0.0001) remained lower, whereas total/HDL-cholesterol ratio (P <0.01), triglycerides, and fibrinogen levels (P <0.05) remained higher than controls. In conclusion, GH discontinuation is inappropriate in adolescents with severe GHD, inducing impairment of lipid profile and cardiac morphology and performance. Because the results on the cardiovascular system and on the lipid profile were suboptimal, it is likely that the GH dose in severe GHD adolescents should be higher.

UR - http://www.scopus.com/inward/record.url?scp=0036348464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036348464&partnerID=8YFLogxK

U2 - 10.1210/jc.87.8.3650

DO - 10.1210/jc.87.8.3650

M3 - Article

C2 - 12161490

AN - SCOPUS:0036348464

VL - 87

SP - 3650

EP - 3655

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 8

ER -